Meptazinol

Meptazinol
  • CAS No.:54340-58-8

Important Notice

  1. This product is a chemical product/pharmaceutical intermediate. It is not a drug, an active pharmaceutical ingredient (API), or a pharmaceutical-grade material. It has not been granted a drug approval number or a Chemical Drug Substance Approval Notice, has not passed drug-related review and approval, and is not manufactured, tested, or released in accordance with pharmaceutical GMP.
  2. This product is intended solely for non-clinical research, process development, quality studies, further chemical processing, or chemical synthesis. It must not be used in drug-product manufacturing, clinical trials, clinical diagnosis, or administration to humans or animals, or be sold, used as an input, submitted for regulatory filing, or released as an API or pharmaceutical material.
  3. The purchaser must not use this product, or supply it to another party, for personal consumption, sports or fitness, weight loss, health supplements, food, or animal feed.
Other grades of this product :
Meptazinol Basic information
Product Name:Meptazinol
Synonyms:MEPTAZINOL;3-(3-ethylhexahydro-1-methyl-1h-azepin-3-yl)-phenol;3-(1-Methyl-3-ethylhexahydro-1H-azepine-3-yl)phenol;(+/-)-3-(3-ethyl-1-Methylhexahydro-1H-azepin-3-yl)phenol;Meptazinol A;3-(3-ethyl-1-Methylazepan-3-yl)phenol;MeptaMizol;Meptazinol-13C-d3
CAS:54340-58-8
MF:C15H23NO
MW:233.35
EINECS:259-109-9
Product Categories:
Mol File:54340-58-8.mol
Meptazinol Chemical Properties
Melting point 127-133°C
Boiling point 354.8±35.0 °C(Predicted)
density 0.997
pka9.95±0.10(Predicted)
Safety Information
MSDS Information
Meptazinol Usage And Synthesis
OriginatorMeptid,Wyeth,UK,1983
UsesAnalgesic.
Manufacturing Process2-(m-Methoxyphenyl)butyronitrile in dry ether was added to a stirred suspension of sodium amide in liquid ammonia. The mixture was stirred for 30 minutes then ethyl-4-iodobutyrate (99.25 g, 0.4 mol) in dry ether (200 ml) was added dropwise. The mixture was stirred at the temperature of refluxing liquid ammonia for 5 hours. Ammonium chloride (10 g) was added and the mixture allowed to warm to room temperature. Water (300 ml) was added, the organic layer separated, washed with water, 2 N sulfuric acid and water. After drying over magnesium sulfate and removing the ether, the product was distilled yielding ethyl 5-cyano-5-(mmethoxyphenyl)heptanoate. That material was hydrogenated in cyclohexane using a Raney nickel catalyst. The product after distillation was recrystallized from ethyl acetate affording 10.0 g of 6-ethyl-(m-methoxyphenyl)hexahydro-2H-azepin-2one, MP 87°C to 88°C. The azepinone (9.1 g) in dry tetrahydrofuran (50 ml) and ether (50 ml) was added dropwise to a stirred suspension of aluminum lithium hydride (7.5 g) in dry ether (50 ml). After heating under reflux for 3 hours the reaction mixture was worked up and distilled yielding 7.66 g of a compound which was a colorless oil, BP 108°C to 110°C/0.01 mm. That product was then heated under reflux with 50% hydrobromic acid for 1.5 hours. The reaction mixture was evaporated to dryness and reevaporated with three portions of propan-2-ol. The oil obtained was dissolved in propan-2-ol and diluted with ether. 3-Ethyl-3-(m-hydroxyphenyl)hexahydro-1H-azepine was obtained. That material in turn was reductively methylated by hydrogenation in the presence of formaldehyde in absolute ethanol solution to give 3-ethyl-3-(m-methoxyphenyl)-1-methylhexahydro-1H-azepine. The methoxy group was converted to a hydroxy group by refluxing with 80% HBr giving meptazinol hydrobromide.
Therapeutic FunctionAnalgesic
Clinical UseOpioid analgesic used for moderate to severe pain
Drug interactionsPotentially hazardous interactions with other drugsAntidepressants: possible CNS excitation or depression with MAOIs - avoid; possible CNS excitation or depression with moclobemide; possibly increased sedative effects with tricyclics. Antihistamines: increased sedative effects with sedating antihistamines. Antipsychotics: enhanced hypotensive and sedative effects. Dopaminergics: avoid with selegiline. Nalmefene: avoid concomitant use. Sodium oxybate: enhanced effect of sodium oxybate - avoid
MetabolismMeptazinol is extensively metabolised in the liver and is excreted mainly in the urine as the glucuronide conjugate. Less than 10% of a dose has been recovered from the faeces.
Meptazinol Preparation Products And Raw materials
Raw materialsSodium amide-->Hydrogen-->Lithium Aluminum Hydride-->Hydrogen bromide-->Formaldehyde-->ETHYL 4-IODOBUTYRATE

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Read the full Disclaimer
Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye